In This Article:
As global markets react to a cooling U.S. labor market and mixed economic data, small-cap stocks have faced significant volatility, with the Russell 2000 Index pulling back sharply. Despite this, opportunities remain for discerning investors who can identify undervalued small-cap companies showing signs of insider action. In today's market conditions, a good stock often combines strong fundamentals with strategic insider buying, indicating confidence from those closest to the company.
Top 10 Undervalued Small Caps With Insider Buying
Name | PE | PS | Discount to Fair Value | Value Rating |
---|---|---|---|---|
Columbus McKinnon | 20.5x | 0.9x | 44.18% | ★★★★★★ |
Nexus Industrial REIT | 2.6x | 3.2x | 26.24% | ★★★★★☆ |
PCB Bancorp | 10.4x | 2.6x | 46.09% | ★★★★★☆ |
Primaris Real Estate Investment Trust | 10.7x | 2.9x | 46.84% | ★★★★★☆ |
AtriCure | NA | 2.3x | 49.13% | ★★★★★☆ |
Hemisphere Energy | 6.7x | 2.4x | 15.73% | ★★★★☆☆ |
Russel Metals | 11.0x | 0.5x | 47.56% | ★★★★☆☆ |
Guardian Capital Group | 10.4x | 4.0x | 38.78% | ★★★★☆☆ |
CVS Group | 22.5x | 1.2x | 40.83% | ★★★★☆☆ |
Community West Bancshares | 18.7x | 2.9x | 42.25% | ★★★☆☆☆ |
Let's dive into some prime choices out of from the screener.
Assura
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Assura is a UK-based real estate investment trust specializing in the development and management of primary care medical centers, with a market cap of approximately £2.08 billion.
Operations: Assura's primary revenue stream is from its core operations, generating £157.8 million in the latest period. The company has experienced fluctuations in net income margins, with recent periods showing negative margins such as -0.18% and -1.10%. Gross profit margin has shown a slight downward trend, reaching 90.81% in the most recent period.
PE: -43.7x
Assura, a specialist healthcare property investor, recently announced a GBP 250 million joint venture with Universities Superannuation Scheme Limited to support NHS infrastructure. Despite reporting a net loss of GBP 28.8 million for the year ending March 2024, earnings are forecast to grow by 40.91% annually. Notably, insiders have shown confidence through recent share purchases in the last quarter of 2023 and early 2024. The company’s strategic acquisitions and partnerships highlight its potential for future growth in the healthcare sector.
GHCL
Simply Wall St Value Rating: ★★★★☆☆
Overview: GHCL is a diversified company primarily engaged in the production of inorganic chemicals, with a market cap of ₹3.27 billion.